GBP/RUB Price & Performance (GBPRUB)

Lixte Biotechnology Holdings has terminated its sales agreement with WallachBeth Capital LLC, effective March 18, 2025. The decision follows a 42% year-to-date decline in its stock value. The company is now exploring alternative funding options to secure equity capital, signaling a shift in its financial strategy.1

Lixte Biotechnology faces potential delisting from the Nasdaq Capital Market for not meeting minimum equity requirements. The company has submitted a compliance plan and awaits a hearing, which could extend the deadline to August 2025. Meanwhile, it continues efforts to stabilize its financial position through capital-raising measures.1

Lixte Biotechnology announced the resignation of its COO, Eric Forman, effective December 31, 2024. This adds to its current challenges, including financing issues and a potential Nasdaq delisting. The company has yet to name a successor or clarify its transition plan, leaving investors with unanswered questions.1